生物类似药(YD057)与杜拉鲁肽关键质量属性比对研究

代亚东, 彭红卫, 苟凡铖, 侯怡铃, 丁祥

中国药学杂志 ›› 2018, Vol. 53 ›› Issue (4) : 300-305.

PDF(2012 KB)
PDF(2012 KB)
中国药学杂志 ›› 2018, Vol. 53 ›› Issue (4) : 300-305. DOI: 10.11669/cpj.2018.04.012
论著

生物类似药(YD057)与杜拉鲁肽关键质量属性比对研究

  • 代亚东, 彭红卫, 苟凡铖, 侯怡铃, 丁祥*
作者信息 +

Comparison Study on the Critical Quality Attributes between Similar Biological Medicine(YD057) and Dulaglutide

  • DAI Ya-dong, PENG Hong-wei, GOU Fan-cheng, HOU Yi-ling, DING Xiang*
Author information +
文章历史 +

摘要

目的 通过基因重组表达的生物类似药GLP-1-Fc融合蛋白(YD057)与上市产品杜拉鲁肽进行关键质量属性比对研究,分析其有无显著差异。方法 采用聚丙烯酰胺凝胶电泳(SDS-PAGE)、分子排阻色谱法(SEC)、毛细管电泳法(CE-SDS)、毛细管等电聚焦(CIEF)分析其理化性质在相对分子质量、纯度、电荷异质性是否存在差异,通过肽图分析其在氨基酸一级序列是否一致,通过寡糖分布测定N糖修饰比例是否一致,在体外生物学活性测定以及GLP-1受体结合力分析来评价细胞学功能与分子结合力方面是否一致。结果 生物类似药(YD057)与杜拉鲁肽在理化性质、氨基酸一级序列、N糖修饰比例、细胞生物学功能与受体结合力都无显著差异。结论 两者关键质量属性(CQA)基本一致。

Abstract

OBJECTIVE To investigate whether there is significant difference between the GLP-1-Fc fusion protein(YD057) that is expressed by gene recombination and the marketed drug dulaglutide(Lilly). METHODS SDS-PAGE, SEC, CE-SDS and CIEF were used to analyze the differences in molecular weight, purity and charge heterogeneity. The amino acid sequence, biological activity and receptor binding analysis were measured to assess whether the cytological function and molecular binding capacity were consistent. Oligosaccharide distribution was measured to assess whether N-linked glycosylation modification ratio was consistent. RESULTS There was no significant difference in physicochemical properties, amino acid primary sequence, N-linked glycosylation modification ratio, cell biology function and receptor binding capacity between the biological similar drugs(YD057) and dulaglutide. CONCLUSION Their critical quality attributes are basically the same.

关键词

生物类似药 / 杜拉鲁肽 / 关键质量属性

Key words

biosimilar / dulaglutide / critical quality attributes

引用本文

导出引用
代亚东, 彭红卫, 苟凡铖, 侯怡铃, 丁祥. 生物类似药(YD057)与杜拉鲁肽关键质量属性比对研究[J]. 中国药学杂志, 2018, 53(4): 300-305 https://doi.org/10.11669/cpj.2018.04.012
DAI Ya-dong, PENG Hong-wei, GOU Fan-cheng, HOU Yi-ling, DING Xiang. Comparison Study on the Critical Quality Attributes between Similar Biological Medicine(YD057) and Dulaglutide[J]. Chinese Pharmaceutical Journal, 2018, 53(4): 300-305 https://doi.org/10.11669/cpj.2018.04.012
中图分类号: R917   

参考文献

[1] GUTZWILLER J P, TSCHOPP S, BOCK A, et al. Glucagon-like peptide-1 induces natriuresis in healthy subjects and in insulin resistant obesemen [J]. J Clin Endocrinol Metab, 2004,89(6):3055-3061.
[2] SONG X Y, HE W J, SUN X Y, et al. Glucagon-like peptide-1 and pancreatic β cells[J]. Lett Biotechnol(生物技术通讯),2015,26(4):579-582.
[3] NIE X H, ZHANG T, ZHENG X F, et al. Interaction between glucagon-like peptide-1 and its receptor[J]. Lett Biotechnol(生物技术通讯),2010,21(2):270-274.
[4] MEIER J J, NAUCK M A. Glucagon-like peptide 1(GLP-1) inbiology and pathology[J]. Diabetes Metab Res Rev, 2005, 21(2):91-117.
[5] MOENS K, HEIMBERG H, FLAMEZ D, et al. Expression and functional activity of glucagon, glucagon-like activity peptide 1, and glucose-dependent insulinotrophic peptide receptors in rat pancreatic islet cells[J]. Diabetes, 1996, 45(2):257-261.
[6] DURING M J, CAO L, ZUZGA D S, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection[J]. Nat Med, 2003,9(9):1173-1179.
[7] DRUCKER D J. Glucagon-like peptide-1 and the islet beta-cell augmentation of cell proliferation and inhibition of apoptosis[J]. Endocrinology, 2003, 144(12):5145-5148.
[8] KUMAR M, HUNAG Y, GLINKA Y, et al. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes[J]. Gene Ther, 2007, 14(12):162-172.
[9] BAGGIO L L, KIM J G, DRUCKER D J. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptordesensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo[J]. Diabetes, 2004,53(suppl 3):205-214.
[10] BAI Y,WANG H X,XIE S M, et al. Development and evaluation of biosimilars(drafting)[J]. Chin J New Drugs(中国新药杂志),2015,24(20):2308-2311.

基金

国家自然科学基金资助项目(31400016, 31200012)
PDF(2012 KB)

Accesses

Citation

Detail

段落导航
相关文章

/